Concordance of HER2 expression in paired primary and metastatic sites of gastric and gastro-oesophageal junction cancers

Ferlay, 2010 Siegel, 2012, Cancer statistics, 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138 Ross, 1999, The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy, Semin Cancer Biol, 9, 125, 10.1006/scbi.1998.0083 Yonemura, 1991, Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer, Cancer Res, 51, 1034 Jorgensen, 2010, Targeted HER2 treatment in advanced gastric cancer, Oncology, 78, 26, 10.1159/000288295 Gravalos, 2008, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol, 19, 1523, 10.1093/annonc/mdn169 Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X Martin, 1986, Abdominal fluid cytology in patients with gastrointestinal malignant lesions, Mayo Clin Proc, 61, 467, 10.1016/S0025-6196(12)61982-X Park, 2014, Clinicopathological features and prognostic significance of HER2 expression in gastric cancer, Oncology, 88, 147, 10.1159/000368555 Lee, 2011, Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections, Histopathology, 59, 832, 10.1111/j.1365-2559.2011.04017.x Ruschoff, 2010, HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing, Virchows Arch, 457, 299, 10.1007/s00428-010-0952-2 Fox, 2012, Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia, Am J Surg Pathol, 36, 577, 10.1097/PAS.0b013e318244adbb Hofmann, 2008, Assessment of a HER2 scoring system for gastric cancer: results from a validation study, Histopathology, 52, 797, 10.1111/j.1365-2559.2008.03028.x Kumarasinghe, 2014, HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio, Pathology, 46, 184, 10.1097/PAT.0000000000000075 Wolff, 2007, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Arch Pathol Lab Med, 131, 18, 10.5858/2007-131-18-ASOCCO Albarello, 2011, HER2 testing in gastric cancer, Adv Anat Pathol, 18, 53, 10.1097/PAP.0b013e3182026d72 Chen, 2013, Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis, Arch Med Res, 44, 380, 10.1016/j.arcmed.2013.07.001 Shan, 2013, HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population, Diagn Pathol, 8, 76, 10.1186/1746-1596-8-76 Gomez-Martin, 2011, Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma, Clin Transl Oncol, 13, 636, 10.1007/s12094-011-0709-7 Kim, 2011, Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays, Ann Surg Oncol, 18, 2833, 10.1245/s10434-011-1695-2 Chan, 2012, A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease, BMC Cancer, 12, 555, 10.1186/1471-2407-12-555 Chang, 2011, Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab, Jpn J Clin Oncol, 41, 593, 10.1093/jjco/hyr020 Bozzetti, 2011, Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma, Br J Cancer, 104, 1372, 10.1038/bjc.2011.121 Reichelt, 2007, Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus, Mod Pathol, 20, 120, 10.1038/modpathol.3800712 Kochi, 2013, Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes, Diagn Pathol, 8, 191, 10.1186/1746-1596-8-191 Shibata, 2014, Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer, Mol Clin Oncol, 2, 751, 10.3892/mco.2014.329 Kim, 2011, Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma, Histopathology, 59, 822, 10.1111/j.1365-2559.2011.04012.x Cho, 2013, A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages, Ann Surg Oncol, 20, S477, 10.1245/s10434-012-2818-0 Kim, 2014, Human epidermal growth factor receptor 2 testing in gastric cancer: Recommendations of an Asia-Pacific Task Force, Asia Pac J Clin Oncol, 10, 297, 10.1111/ajco.12263 Hechtman, 2012, HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications, Arch Pathol Lab Med, 136, 691, 10.5858/arpa.2011-0168-RS Wong, 2015, HER2 testing in malignant effusions of metastatic gastric carcinoma: Is it feasible, Diagn Cytopathol, 43, 80, 10.1002/dc.23212